InvestorsHub Logo
Followers 63
Posts 7611
Boards Moderated 1
Alias Born 01/02/2003

Re: None

Monday, 06/06/2022 9:52:26 AM

Monday, June 06, 2022 9:52:26 AM

Post# of 430302
Amarin is a text book example of the outcomes when a one product drug company loses its exclusivity for it's primary indication to a skinny label...theoretically marketed by a generic only for a for a secondary indication...but, in reality, the generic company counting on making most of its sales for the primary indication.

The case of Amarin vs. Hikma points out some serious flaws in the H-W law.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News